Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00633841
Recruitment Status : Completed
First Posted : March 12, 2008
Last Update Posted : October 19, 2010
Information provided by:
Affiris AG

March 5, 2008
March 12, 2008
October 19, 2010
February 2008
September 2009   (Final data collection date for primary outcome measure)
Tolerability [ Time Frame: 1 year ]
Same as current
Complete list of historical versions of study NCT00633841 on Archive Site
Immunological and clinical efficacy (evaluated in explorative manner) [ Time Frame: 1 year ]
Same as current
Not Provided
Not Provided
Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
Randomized, Controlled, Parallel Group, Patient-Blinded, Single-Center Phase I Pilot Study to Assess Tolerability and Safety of Repeated s.c. Administration of a Single-Dose of AFFITOPE AD02 Applied With or Without Adjuvant to Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the tolerability and safety of repeated subcutaneous injection of a single dose of AFFITOPE AD02 in patients with mild to moderate Alzheimer's Disease.

Alzheimer's Disease (AD) is a devastating neurodegenerative disorder for which there is no cure.

Although the etiology of AD is not fully understood, recent research suggests that Aβ is central to the disease process. Consequently, approaches capable of removing Aβ from the brain, such as Aβ immunotherapy, are expected to possess disease-modifying potential. This view is supported by evidence gathered in mouse models of AD and studies involving AD patients.

Based on the view that active Aβ immunotherapy has disease-modifying potential both in animal models of AD and in patients, and on the knowledge gathered on the side-effects of Aβ-based immunotherapy encountered in humans, we designed a new generation of AD vaccines. Rather than using full length Aβ itself, we choose to use mimotopes of the N-terminal end of Aβ as the antigenic component of our vaccine (Mimotopes discovered by Affiris GmbH have been termed AFFITOPES). Mimotopes are peptides that functionally mimic the native antigenic epitope but do not show sequence identity to it. Thus, while being different from the original antigen, mimotopes are recognized by the same antibodies and, vice versa, are capable of inducing antibodies that cross-react with the original antigen itself. A major advantage offered by mimotopes is the lack of tolerance mechanisms that would prevent the induction of an immune response to it (as is the case with self peptides/proteins such as Aβ). To further increase the vaccine's safety profile, the length of the mimotope used was limited to preclude the elicitation of Aβ-specific T cells. Also, the mimotope used has been designed to generate antibodies directed exclusively to Aβ (i.e., they do not recognize parental APP itself). To provide helper epitopes for the generation of an antibody response, the mimotope is coupled to a carrier.

The trial is designed as a patient-blinded, single-center, randomized, controlled, parallel group, phase I clinical study of repeated once every 4 weeks administration by subcutaneous injection of AFFITOPE AD02 alone or adsorbed to aluminium hydroxide in 24 patients with mild to moderate Alzheimer's Disease. In total, each patient will receive 4 immunizations. Patients will be randomized to receive AFFITOPE AD02 alone or adsorbed to alumimium hydroxide. Each treatment group consists of 12 patients. For safety reasons, inclusion of patients will be done in a stepwise manner.

Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Alzheimer's Disease
Biological: AFFITOPE AD02
4 subcutaneous injections of IP in 4-week intervals
  • Active Comparator: 1
    AFFITOPE AD02 without adjuvant
    Intervention: Biological: AFFITOPE AD02
  • Active Comparator: 2
    AFFITOPE AD02 with adjuvant
    Intervention: Biological: AFFITOPE AD02
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
September 2009
September 2009   (Final data collection date for primary outcome measure)

Main Inclusion Criteria:

  • Diagnosis of probable Alzheimer's disease based on the NINCDS/ADRDA criteria.
  • Alzheimer's disease of mild to moderate degree (MMSE 16-26)
  • Magnetic Resonance Imaging scan (MRI) of brain consistent with diagnosis of AD.
  • Written informed consent signed and dated by the patient and the caregiver.
  • Age 50-80 years.
  • Availability of a partner/caregiver

Other Inclusion Criteria apply.

Main Exclusion Criteria:

  • Presence or history of allergy to components of the vaccine.
  • Contraindication for MRI imaging.
  • Participation in another clinical trial.
  • Prior and/or current treatment with experimental immunotherapeutics including IVIG or vaccines for AD.
  • Prior and/or current treatment with immunosuppressive drugs
  • History and/or presence of autoimmune disease.

Other Exclusion Criteria apply.

Sexes Eligible for Study: All
50 Years to 80 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Affiris 002
Not Provided
Not Provided
Affiris GmbH
Affiris AG
Not Provided
Principal Investigator: Margot Schmitz, Univ. Doz. Dr. Ordination Univ. Doz. Dr. Margot Schmitz
Affiris AG
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP